Chemical subgroup
L04AC – Interleukin-Inhibitoren
39Decisions
67Patient groups
Added benefit by patient group
- Considerable7
- Minor10
- Non-quantifiable2
- Not proven48
Decisions, newest first
- 2026-06-18TremfyaGuselkumabNot proven
- 2026-03-19TaltzIxekizumabNot proven
- 2026-03-19TaltzIxekizumabNot proven
- 2025-11-20TremfyaGuselkumabNot proven: 2 of 2 patient groups
- 2025-11-20TremfyaGuselkumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-09-04OmvohMirikizumabNot proven: 2 of 2 patient groups
- 2025-08-07KevzaraSarilumabNot proven: 2 of 2 patient groups
- 2025-08-07KevzaraSarilumabNot proven
- 2025-02-20SkyriziRisankizumabNot proven: 2 of 2 patient groups
- 2024-11-22BimzelxBimekizumabNot proven
- 2024-01-18OmvohMirikizumabNot proven: 2 of 2 patient groups
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-07CosentyxSecukinumabNot proven
- 2023-07-20SpevigoSpesolimabNot proven
- 2023-06-15SkyriziRisankizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-01-05CosentyxSecukinumabNot proven
- 2023-01-05CosentyxSecukinumabNot proven
- 2022-05-19SkyriziRisankizumabNot proven: 2 of 2 patient groups
- 2022-03-03BimzelxBimekizumabMinor: 2 of 2 patient groups
- 2022-01-06EnspryngSatralizumabMinor
- 2021-05-20TremfyaGuselkumabNot proven: 2 of 2 patient groups
- 2021-02-18CosentyxSecukinumabNot proven
- 2021-02-18CosentyxSecukinumabMinor
- 2021-02-18CosentyxSecukinumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-01-21TaltzIxekizumabNot proven
- 2021-01-21TaltzIxekizumabNot proven: 3 of 3 patient groups
- 2019-11-22SkyriziRisankizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-05-02IlumetriTildrakizumabNot proven: 2 of 2 patient groups
- 2018-08-16TaltzIxekizumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2018-05-17TremfyaGuselkumabConsiderable: 2 of 2 patient groups
- 2018-03-01KyntheumBrodalumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-02-15KevzaraSarilumabConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2017-08-17CosentyxSecukinumabConsiderable
- 2017-08-17TaltzIxekizumabConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2016-06-02CosentyxSecukinumabNot proven
- 2015-11-27CosentyxSecukinumabConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2014-12-04SylvantSiltuximabNon-quantifiable
Data status: 2026-10-29